Company Description
Iambic Therapeutics is a technology and clinical-stage life sciences company pursuing a fundamental shift in the biopharmaceutical industry.
Our mission is to make better technology for better medicines. We do this by integrating leading proprietary, large-scale artificial intelligence (AI) with automated, scalable chemistry and biology experimentation.
We call this approach molecular superintelligence. Instead of treating each stage of drug discovery as a distinct technological challenge, we have developed a unified, intelligent platform designed to address the full journey of drug discovery and development—from hit identification to multiparameter lead optimization to clinical developability.
Our proprietary technologies include Enchant, a multimodal AI model for predicting preclinical and clinical properties, NeuralPLexer, a flow-matching generative AI for biomolecular structure prediction, and automated plate-based chemistry and biology workflows that allow synthesis and testing of hundreds of compounds per program on a weekly cadence.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 171 |
| CEO | Thomas Miller, Ph.D. |
Contact Details
Address: 5627 Oberlin Drive, Suite 120 San Diego, CA 92121 United States | |
| Phone | (619) 330-5499 |
| Website | iambic.ai |
Stock Details
| Ticker Symbol | IAM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1997038 |
| Employer ID | 84-3364168 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Thomas Miller, Ph.D. | Chief Executive Officer and Director |
| Frederick Manby, Ph.D. | Chief Technology Officer and Director |
| Neil Josephson, M.D. | Chief Medical Officer |
| Peter Olson, Ph.D. | Chief Scientific Officer |
| Michael Secora, Ph.D. | Chief Financial Officer and Chief Corporate Development Officer |
| Samit Hirawat, M.D. | Director |
| Evan Rachlin, M.D. | Director |
| William Rastetter, Ph.D. | Director |
| Shalini Sharp | Director |
| Mary Tagliaferri, M.D. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 21, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Sep 9, 2026 | D | Notice of Exempt Offering of Securities |
| Aug 28, 2026 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jul 24, 2026 | DRS | [Cover] Draft Registration Statement |
| Apr 8, 2026 | D | Notice of Exempt Offering of Securities |
| Nov 21, 2025 | D | Notice of Exempt Offering of Securities |
| Jun 6, 2024 | D/A | Filing |
| May 7, 2024 | D/A | Filing |
| Apr 25, 2024 | D | Notice of Exempt Offering of Securities |
| Oct 12, 2023 | D | Notice of Exempt Offering of Securities |